# A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants

> **NCT06982131** · PHASE1 · RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 40 (estimated)

## Conditions studied

- Overweight
- Obesity

## Interventions

- **DRUG:** RO7795081
- **DRUG:** Placebo
- **DRUG:** Rosuvastatin
- **DRUG:** Pitavastatin

## Key facts

- **NCT ID:** NCT06982131
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-04
- **Primary completion:** 2026-12-04
- **Final completion:** 2026-12-04
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06982131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06982131, "A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT06982131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*